Hisamitsu Pharmaceutical Co Inc
TSE:4530
Hisamitsu Pharmaceutical Co Inc
Income from Continuing Operations
Hisamitsu Pharmaceutical Co Inc
Income from Continuing Operations Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Income from Continuing Operations | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Hisamitsu Pharmaceutical Co Inc
TSE:4530
|
Income from Continuing Operations
¥16B
|
CAGR 3-Years
17%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
-1%
|
|
|
Takeda Pharmaceutical Co Ltd
TSE:4502
|
Income from Continuing Operations
¥208.2B
|
CAGR 3-Years
-22%
|
CAGR 5-Years
73%
|
CAGR 10-Years
14%
|
|
|
Daiichi Sankyo Co Ltd
TSE:4568
|
Income from Continuing Operations
¥245.5B
|
CAGR 3-Years
37%
|
CAGR 5-Years
11%
|
CAGR 10-Years
14%
|
|
|
Otsuka Holdings Co Ltd
TSE:4578
|
Income from Continuing Operations
¥347.3B
|
CAGR 3-Years
39%
|
CAGR 5-Years
21%
|
CAGR 10-Years
9%
|
|
|
Chugai Pharmaceutical Co Ltd
TSE:4519
|
Income from Continuing Operations
¥387.3B
|
CAGR 3-Years
9%
|
CAGR 5-Years
20%
|
CAGR 10-Years
22%
|
|
|
Astellas Pharma Inc
TSE:4503
|
Income from Continuing Operations
-¥57.4B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Hisamitsu Pharmaceutical Co Inc
Glance View
In the bustling landscape of Japanese pharmaceutical companies, Hisamitsu Pharmaceutical Co., Inc. stands out with its pioneering spirit and deep-rooted dedication to health and wellness. Founded in 1847, the company has evolved over a century and a half, transitioning from a modest establishment selling herbal medicines to a globally recognized manufacturer of pain-relief products. At the core of Hisamitsu's operations is its flagship product, the transdermal patch, featuring the SALONPAS brand as its crown jewel. This innovative delivery system allows active medicinal ingredients to penetrate the skin, addressing pain at its source effectively and efficiently. As global demand for non-invasive pain relief grows, Hisamitsu leverages its expertise in transdermal technology, continuously innovating and expanding its product line to cater to diverse consumer needs. Hisamitsu's success hinges on a solid blend of cutting-edge research, consistent quality, and strategic marketing prowess. By investing heavily in R&D, the company not only enhances its existing product offerings but also explores new therapeutic areas, ensuring a pipeline poised for future growth. Besides Japan, Hisamitsu's market presence extends across the Americas, Europe, and Asia, with international sales contributing significantly to its revenue stream. The company is adept at navigating intricate regulatory landscapes and varying consumer preferences to establish its footprint globally. This strategic expansion, coupled with a relentless commitment to quality, enables Hisamitsu to sustain its profitability while fulfilling its mission of delivering comfort and improved quality of life to people around the world.
See Also
What is Hisamitsu Pharmaceutical Co Inc's Income from Continuing Operations?
Income from Continuing Operations
16B
JPY
Based on the financial report for Nov 30, 2024, Hisamitsu Pharmaceutical Co Inc's Income from Continuing Operations amounts to 16B JPY.
What is Hisamitsu Pharmaceutical Co Inc's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 10Y
-1%
Over the last year, the Income from Continuing Operations growth was 8%. The average annual Income from Continuing Operations growth rates for Hisamitsu Pharmaceutical Co Inc have been 17% over the past three years , -6% over the past five years , and -1% over the past ten years .
You don't have any saved screeners yet